Cantor Fitzgerald Predicts CLDX FY2026 Earnings

Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) - Cantor Fitzgerald issued their FY2026 earnings per share estimates for Celldex Therapeutics in a research report issued to clients and investors on Monday, June 9th. Cantor Fitzgerald analyst K. Kluska anticipates that the biopharmaceutical company will post earnings of ($4.68) per share for the year. The consensus estimate for Celldex Therapeutics' current full-year earnings is ($2.48) per share.

A number of other research firms also recently issued reports on CLDX. Canaccord Genuity Group began coverage on Celldex Therapeutics in a research note on Monday, April 28th. They issued a "buy" rating and a $64.00 target price on the stock. UBS Group lowered their price objective on Celldex Therapeutics from $44.00 to $38.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. Morgan Stanley cut their target price on shares of Celldex Therapeutics from $46.00 to $43.00 and set an "overweight" rating for the company in a research report on Friday, May 9th. The Goldman Sachs Group lowered their price target on shares of Celldex Therapeutics from $36.00 to $31.00 and set a "neutral" rating on the stock in a research report on Friday, May 9th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a report on Tuesday, May 6th. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $53.90.

Celldex Therapeutics Trading Up 1.0%

Shares of NASDAQ:CLDX traded up $0.21 during mid-day trading on Tuesday, reaching $20.92. The company had a trading volume of 992,491 shares, compared to its average volume of 918,673. Celldex Therapeutics has a one year low of $14.40 and a one year high of $47.00. The company's 50-day moving average price is $19.05 and its 200-day moving average price is $21.90. The firm has a market cap of $1.39 billion, a price-to-earnings ratio of -8.14 and a beta of 1.33.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). The company had revenue of $0.70 million during the quarter, compared to analysts' expectations of $1.08 million. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%.

Institutional Trading of Celldex Therapeutics

Large investors have recently modified their holdings of the business. EverSource Wealth Advisors LLC raised its position in Celldex Therapeutics by 215.7% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company's stock valued at $32,000 after purchasing an additional 878 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of Celldex Therapeutics by 6,665.9% during the 1st quarter. GAMMA Investing LLC now owns 2,977 shares of the biopharmaceutical company's stock valued at $54,000 after buying an additional 2,933 shares in the last quarter. Headlands Technologies LLC purchased a new position in shares of Celldex Therapeutics during the 4th quarter valued at about $81,000. AlphaQuest LLC lifted its position in Celldex Therapeutics by 171.0% in the 4th quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company's stock worth $108,000 after buying an additional 2,705 shares during the last quarter. Finally, Aquatic Capital Management LLC purchased a new stake in Celldex Therapeutics in the fourth quarter worth approximately $121,000.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.